Exelixis Net Worth
Exelixis Net Worth Breakdown | EXEL |
Exelixis Net Worth Analysis
Exelixis' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Exelixis' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Exelixis' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Exelixis' net worth analysis. One common approach is to calculate Exelixis' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Exelixis' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Exelixis' net worth. This approach calculates the present value of Exelixis' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Exelixis' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Exelixis' net worth. This involves comparing Exelixis' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Exelixis' net worth relative to its peers.
Enterprise Value |
|
To determine if Exelixis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exelixis' net worth research are outlined below:
| Exelixis has a strong financial position based on the latest SEC filings | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Techne Up 2.2 percent Since Last Earnings Report Can It Continue |
Exelixis Quarterly Good Will |
|
Exelixis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exelixis. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exelixis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Exelixis' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exelixis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exelixis backward and forwards among themselves. Exelixis' institutional investor refers to the entity that pools money to purchase Exelixis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 4.1 M | Stephens Inv Mgmt Group Llc | 2024-09-30 | 3.8 M | Aqr Capital Management Llc | 2024-06-30 | 3.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 3.3 M | Norges Bank | 2024-06-30 | 2.8 M | Bank Of New York Mellon Corp | 2024-06-30 | 2.7 M | First Trust Advisors L.p. | 2024-06-30 | 2.6 M | Fmr Inc | 2024-09-30 | 2.5 M | Jupiter Asset Management Limited | 2024-09-30 | 2.2 M | Blackrock Inc | 2024-06-30 | 33.5 M | Vanguard Group Inc | 2024-09-30 | 29.3 M |
Follow Exelixis' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.41 B.Market Cap |
|
Project Exelixis' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.13 | 0.13 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.10 | 0.10 |
When accessing Exelixis' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Exelixis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exelixis' profitability and make more informed investment decisions.
Evaluate Exelixis' management efficiency
Exelixis has return on total asset (ROA) of 0.1281 % which means that it generated a profit of $0.1281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.202 %, meaning that it created $0.202 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Exelixis' Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.13 this year, although the value of Return On Equity will most likely fall to 0.10. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Intangibles To Total Assets will most likely fall to 0.02.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.02 | 7.37 | |
| Tangible Book Value Per Share | 6.82 | 7.16 | |
| Enterprise Value Over EBITDA | 17.18 | 18.04 | |
| Price Book Value Ratio | 2.60 | 4.24 | |
| Enterprise Value Multiple | 17.18 | 18.04 | |
| Price Fair Value | 2.60 | 4.24 | |
| Enterprise Value | 1.4 B | 1.9 B |
Exelixis benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 4.4515 | Revenue 2.1 B | Quarterly Revenue Growth 0.143 | Revenue Per Share 7.032 | Return On Equity 0.202 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exelixis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Exelixis Corporate Filings
F4 | 26th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Exelixis Earnings per Share Projection vs Actual
Exelixis Corporate Management
| Amy MD | Product VP | Profile | |
| Laura Dillard | Executive Resources | Profile | |
| Tony Redmond | Senior Resources | Profile | |
| Gregg Bernier | VP Marketing | Profile | |
| William MD | Senior Affairs | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.